GPC3 and hepatocellular carcinoma: According to novel advances in the management of HCC reported by Llovet et al. (61) in 2008, high accuracy rates have been presented by a 3-gene set, glypican-3, LYVE1 (lymphatic vessel endothelial hyaluronan receptor-1), and survivin.